Network
Hypo-RESOLVE unites leading healthcare players as well as patient organisations from all over Europe and the United States

THE LEONA M. AND HARRY B. HELMSLEY CHARITABLE TRUST (HCT)
United States

The Helmsley Charitable Trust aspires to improve lives by supporting exceptional efforts in the U.S. and around the world in health and select place-based initiatives. Since beginning active grantmaking in 2008, Helmsley has committed more than $2 billion for a wide range of charitable purposes. Helmsley’s Type 1 Diabetes Program was established with the goal of improving the lives of all people living with type 1 diabetes (T1D). It is one of the largest private foundation funders of T1D in the nation. Working closely with key players across the T1D ecosystem – patients, physicians, researchers, caregivers, researchers, government agencies, funders, pharmaceutical companies, device makers, and community organizations – we seek to improve care and ultimately prevent the disease. We hope to do so by supporting innovative projects that are high-risk, high-reward, and have a long-term vision. We encourage bold thinking and new approaches, supporting projects that others cannot fund but have a clear impact on the lives of people with T1D.

Helmsley is providing $500,000 in funding per year for three years to this project (totaling $1.5M). This funding is awarded with the driving vision of better understanding hypoglycemia, a dangerous complication of T1D and a constant concern for many.

Sean Sullivan will be the Helmsley contact for this project. He will take part in the General Assembly as well as the Managing Board.

Dr Sean Sullivan

Program Officer for the Helmsley Charitable Trust’s Type 1 Diabetes (T1D) Program. In this role, he oversees the glucose control grants portfolio, identifying and evaluating new devices and technologies with the goal of improving glucose control while reducing the burden for people living with T1D.

Previously, Sean was a staff engineer in diabetes care research and development at Becton Dickinson. There, his focus was on new product development, where he led and was part of a number of cross-functional teams to bring new diabetes injection devices to market. With considerable expertise in technology assessment, market research, and intellectual property, Sean is the author of a number of peer-reviewed publications and multiple U.S. and world patents.

Sean earned a joint PhD in Biomedical Engineering from Georgia Institute of Technology and Emory University and a Bachelor of Science degree in Chemical Engineering from the University of Notre Dame.

T1D Exchange